CHEVRIER , Marion

Last name: CHEVRIER

First name: Marion

September 19, 2024 (v1)

Journal article

Metadata-only

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Alcantara, Marion Chevrier, Marion Jardin, Fabrice

Background: Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual use in combination with high-dose methotrexate-based...

Uploaded on: October 4, 2024
June 2, 2023 (v1)

Conference paper

Metadata-only

Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL)

Alcantara, Marion Chevrier, Marion Jardin, Fabrice

International audience

Uploaded on: October 11, 2023
May 2020 (v1)

Journal article

Metadata-only

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Vasseur, Antoine Cabel, Luc Trédan, Olivier

Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).

Uploaded on: December 4, 2022

CHEVRIER , Marion

Recent uploads